Four Asean nations among 38 to get Avigan drug from Japan for clinical trial


BANGKOK (The Nation/ANN): Japan is preparing to send Avigan, a drug used for treating influenza, to 38 countries this week, with four Asean countries -- the Philippines, Malaysia, Indonesia and Myanmar -- joining the trial for Covid-19 patients.

Japan's Minister for Foreign Affairs Toshimitsu Motegi said that Avigan, also known as Favipiravir, would be dispatched this week free of charge to be used in experiments to treat patients with Covid-19.

"The drug is effective in treating patients with Covid-19, especially in people with mild symptoms," added Motegi.

Motegi said Japan would work with countries receiving the drug to expand clinical research on the efficacy of treating patients with Covid-19

.Japan will also give US$1 million to the United Nations to buy and deliver the medicine to the countries in need.- The Nation/Asia News Network

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Asean , Avigan , Japan , clinical , trials , free , drug , Favipiravir

Next In Regional

TikTok darling and Cambodia's famous daughter Princess Norodom Jenna will headline the opening ceremony of the Asean Hyundai Cup
Trump touts Iran inspection deal as Tehran disputes claim
9.3 million�illicit cigarettes seized by Customs
Japan 'robot wolves' in high demand to scare off bears
Lula won’t sideline China or anyone in rare earths, tells Trump refining stays in Brazil
Asean still not ready to accept Myanmar leaders at summits, meetings, says Tok Mat
Anwar holds bilateral talks with S'pore, Laos counterparts
Asean vows to avoid export bans, share fuel as oil prices soar
China AI robot restaurant analyses diners’ faces, tongues to recommend health-focused dishes
Why China’s humanoid robots are still waiting for their ‘ChatGPT moment’

Others Also Read